| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allovir, Inc. | Chief Commercial Officer | Common Stock | 147,000 | $98,608 | $0.6708 | 03 Jul 2023 | Direct |
| Adaptimmune Therapeutics PLC | Chief Commercial Officer | American Depositary Shares representing Ordinary Shares | 18,421 | $10,588 | $0.5748 | 15 Jan 2025 | Direct |
| Adaptimmune Therapeutics PLC | Chief Commercial Officer | Option to purchase Ordinary Shares | 1,074,696 | 20 Feb 2025 | Direct | ||
| Allovir, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 273,000 | 03 Jul 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics PLC | 20 Feb 2025 | 2 | $0 | 4 | Chief Commercial Officer | 20 Feb 2025, 17:32 |
| ADAP | Adaptimmune Therapeutics PLC | 15 Jan 2025 | 1 | -$7,467 | 4 | Chief Commercial Officer | 15 Jan 2025, 16:18 |
| ADAP | Adaptimmune Therapeutics PLC | 18 Jun 2024 | 1 | -$22,814 | 4 | Chief Commercial Officer | 18 Jun 2024, 17:00 |
| ADAP | Adaptimmune Therapeutics PLC | 18 Mar 2024 | 2 | $0 | 4 | Chief Commercial Officer | 18 Mar 2024, 17:00 |
| KLRS | Allovir, Inc. | 03 Jul 2023 | 2 | $0 | 4 | Chief Commercial Officer | 05 Jul 2023, 17:00 |
| KLRS | Allovir, Inc. | 12 Jun 2023 | 0 | $0 | 3 | Chief Commercial Officer | 21 Jun 2023, 17:00 |
| ADAP | Adaptimmune Therapeutics PLC | 31 Jan 2023 | 1 | -$22,230 | 4 | Chief Commercial Officer | 31 Jan 2023, 20:02 |
| ADAP | Adaptimmune Therapeutics PLC | 17 Jan 2023 | 3 | $0 | 4 | Chief Commercial Officer | 17 Jan 2023, 20:02 |
| ADAP | Adaptimmune Therapeutics PLC | 01 Aug 2022 | 1 | -$37,314 | 4 | Chief Commercial Officer | 01 Aug 2022, 21:00 |
| ADAP | Adaptimmune Therapeutics PLC | 31 Jan 2022 | 3 | $0 | 4 | Chief Commercial Officer | 31 Jan 2022, 20:05 |
| ADAP | Adaptimmune Therapeutics PLC | 31 Jan 2022 | 0 | $0 | 3 | Chief Commercial Officer | 31 Jan 2022, 20:00 |